Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLJEFH)

Drug Name
Relacatib Drug Info
Synonyms GSK-462795; SB-462795; Azepan-3-one compound 10; Relacatib (USAN/INN); N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide
Indication
Disease Entry ICD 11 Status REF
Bone metastases 2D50 Discontinued in Phase 2 [1]
Osteoporosis FB83.0 Discontinued in Phase 1 [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [2]
Cross-matching ID
PubChem CID
6918602
CAS Number
CAS 362505-84-8
TTD Drug ID
DMLJEFH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Cathepsin K (CTSK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Odanacatib DM1EO3G Osteoporosis FB83.0 Phase 3 [4]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [5]
VEL-0230 DMDSC63 Rheumatoid arthritis FA20 Phase 1 [6]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [7]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [7]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [7]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [8]
PMID27998201-Compound-15 DMOB8LU Pain MG30-MG3Z Patented [7]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R Pain MG30-MG3Z Patented [7]
PMID27998201-Compound-8 DMZK0SY N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7862).
2 A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.
3 The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8.
4 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
5 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
6 Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
7 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
8 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.